Oral, Blood-Brain Barrier Penetrant CDK4/6 Bifunctional Degrader for Breast Cancer & Other Solid Tumors 

Time: 8:30 am
day: Day 2 AM


  • Highlighting Biotheryx's PRODEGY platform which has enabled the discovery of bifunctional molecules that demonstrate highly selective, rapid, and deep degradation of CDK4 and CDK6
  • Spotlighting BTX-9341's excellent PK/ADME properties and sustained exposure in the brain, which is currently in IND-enabling studies  
  • Demonstrating potent tumor growth inhibition superior to the FDA-approved CDK4/6 inhibitors in breast cancer xenograft studies, including intracranial models